

Penalized Poisson model for network meta-analysis of individual patient time-to-event data

OLLIER Edouard^{1,2,3}, Blanchard Pierre^{2,4}, LE TEUFF Gwénaél^{1,2*}, MICHIELS Stefan^{1,2*}

¹Service de Biostatistique et d'Épidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France

²Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France

³SAINBIOSE U1059, Equipe DVH, Université Jean Monnet, Saint-Etienne, France

⁴ Department de radiotherapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France

*Co-last authors

Corresponding author:

Edouard Ollier

Unité de Recherche Clinique, Innovation, Pharmacologie

Hôpital Nord, CHU de Saint-Etienne, 42055 Saint- Etienne Cedex 2

E-Mail: edouard.ollier@univ-st-etienne.fr

Abstract

Network meta-analysis (NMA) allows the combination of direct and indirect evidence from a set of randomized clinical trials. Performing NMA using individual patient data (IPD) is considered as a “gold standard” approach as it provides several advantages over NMA based on aggregate data. For example, it allows to perform advanced modelling of covariates or covariate-treatment interactions. An important issue in IPD NMA is the selection of influential parameters among terms that account for inconsistency, covariates, covariate-by-treatment interactions or non-proportionality of treatments effect for time to event data. This issue has not been deeply studied in the literature yet and in particular not for time-to-event data. A major difficulty is to jointly account for between-trial heterogeneity which could have a major influence on the selection process. The use of penalized generalized mixed effect model is a solution, but existing implementations have several shortcomings and an important computational cost that precludes their use for complex IPD NMA. In this article, we propose a penalized Poisson regression model to perform IPD NMA of time-to-event data. It is based only on fixed effect parameters which improve its computational cost over the use of random effects. It could be easily implemented using existing penalized regression package. Computer code is shared for implementation. The methods were applied on simulated data to illustrate the importance to take into account between trial heterogeneity during the selection procedure. Finally, it was applied to an IPD NMA of overall survival of chemotherapy and radiotherapy in nasopharyngeal carcinoma.

Key words: network meta-analysis, individual patient data, time-to-event data, penalized likelihood, lasso, frequentist, model selection.

Introduction

Network meta-analyses (NMA) allow the combination of direct and indirect evidence from a set of randomized clinical trials to estimate all pairwise treatment comparisons. Performing NMA using individual patient data (IPD) is considered as a “gold standard” approach as it provides the most accurate estimates of treatments effect and the greatest power to identify relevant covariates or covariate-treatment interactions¹⁻². NMA can be performed directly on the whole individual patient dataset (one stage approach) or using summarized estimates of treatments effect obtained separately by applying a standardized statistical procedure to IPD of each study (two stages approach).

IPD NMA has been well studied for continuous or binary outcomes³⁻⁴ but fewer works have been conducted for time-to-event data. Recently, a one-stage Bayesian approach based on the Royston-Parmar model have been proposed⁵, resulting in a very flexible model. From the frequentist point of view, any methods estimating treatment effect such as the Cox proportional hazard model or the Peto estimator could be used to perform a two-stage IPD NMA⁶. However, in the presence of between-trial heterogeneity and/or non-proportionality of treatment effect, the use of this approach may be suboptimal and one-stage approach are preferable³⁻⁴. For standard IPD meta-analysis, the use of a Poisson generalized mixed linear model have been proposed⁷ and allows to easily perform one stage meta-analysis while accounting for heterogeneity and non-proportionality. Furthermore, this approach relies on the framework of generalized linear models and then benefit from a low computational burden. To our knowledge, this approach has not been yet applied to non-trivial IPD NMA for time-to-event data with more than 3 treatments.

Generally, realization of an IPD NMA faces two key issues. The first one is the quantification of between-trial heterogeneity in treatment effects as for standard MA. Accounting for between-trial heterogeneity becomes mandatory when heterogeneity is large and remain unexplained in order to avoid bias in treatment effect estimations. This can be done by using mixed effects models consisting on inclusion of random effects. Compared to fixed effect models, estimation of mixed effects models requires to solve a complex optimization problem as the likelihood corresponds to a multidimensional integral that is not known explicitly. This is particularly true for IPD NMA, where multiple random effects may be included in the statistical model, making inference particularly complex especially with time-to-event data. The use of Bayesian inference techniques may be a solution as it does not require the use of complex optimization procedure and may explain why NMA commonly use Bayesian modelling.

The second issue is the selection of the network meta-analysis models. Indeed, in NMA several additional parameters could be included in the model. Inconsistency hypothesis violation could be taken into account by including parameters for treatment loops in which

inconsistency is present⁸. Covariates and covariate-by-treatment interactions could be included in the model to account for the association between baseline hazard or treatment effect with some patients' characteristics⁹. With time-to-event data, non-proportionality of treatment effects could also be modeled by including interaction between treatment and follow-up time⁵. All these parameters could be included as fixed regression coefficients, but a selection step has to be performed to define which parameters has to be included. Even if the issue of variables selection is not a high dimensional one as for analysis of genomic data, the size of the set of all possible models grows rapidly with the number of parameters which depends on the geometry of the network defined by the number of treatments (nodes) and connection between treatments (edges). Then it may benefit from an automatic selection routine. Several methods such as stepwise procedures and penalized likelihood approaches are classically used in this context of variables selection and may be directly applied to IPD NMA.

In IPD NMA, the method used to analyze the data need then ideally to perform model selection and jointly take into account between-trials heterogeneity. This may be done by using penalized Generalized Linear Mixed Model (GLMM)¹⁰⁻¹¹. However, such models are particularly difficult to estimate as their likelihood is both not known explicitly and non-differentiable. Several algorithms have been proposed¹⁰⁻¹², but existing implementations have multiple shortcomings. The main one is the impossibility to jointly estimate penalized and unpenalized parameters which is necessary in order not to bias treatments effect estimations. An alternative solution would be to develop a fixed effect model that accounts for between-trial heterogeneity. This could be done by implementing a penalized model in which study specific random effects are treated as fixed effects but penalized in order to ensure identifiability. This would thus increase the number of parameters in the model. This approach has already been used to analyze stratified data with lasso penalty where each parameter is decomposed into a sum of a common effect plus a strata specific parameter¹³.

In this work, we propose a Poisson regression model to perform IPD network meta-analysis of time-to-event data using a frequentist approach. Heterogeneity quantification and model selection effect are performed simultaneously by using a penalized fixed effect model allowing to overcome the optimization problem met when applying random effect models. The proposed method can be easily implemented using existing penalized regression package and R code is shared within the article. Section 2 introduces a NMA in head and neck; section 3 describes our statistical penalized method; section 4 presents the simulation framework; section 5 presents the results of the simulations and the application of our approach to a real example.

NMA of chemotherapy and radiotherapy in nasopharyngeal carcinoma

The IPD NMA of chemotherapy and radiotherapy in nasopharyngeal carcinoma aimed to investigate the benefit of different timing of chemotherapy in addition to a radiotherapy (RT)⁶. The network includes 7 treatments (nodes): RT alone (reference treatment), induction chemotherapy (IC) followed by RT (IC-RT); RT followed by adjuvant chemotherapy (RT-AC); IC followed by RT followed by AC (IC-RT-AC); chemo-radiotherapy (CRT); IC followed by CRT (IC-CRT); and CRT followed by AC (CRT-AC). The network is composed of 4806 individual patient data from 19 trials split into 24 comparisons (edges). The number of trials per comparison varied from 1 to 7. The structure of the network is represented in Figure 1. The original analysis was based on a two-stage fixed effect-model in which treatment effects were estimated separately for each trial based on IPD in a first step and then combined using a NMA in a second step. No covariates effects or covariate-by-treatment interactions were investigated at the time.

Poisson regression model for network meta-analysis

The Poisson regression model has been previously proposed for standard meta-analysis of time-to-event IPD⁷ and may be directly extended to NMA of IPD. In this section, we present its extension in the context of NMA of individual patient time-to-event data studying Q different treatments (one treatment is set as reference):

$$d_{ijk} \sim \mathcal{P}(\mu_{ijk})$$

$$\log(\mu_{ijk}) = \log(\xi_{ijk}) + \pi_k + \gamma_i + \sum_{q=1}^{Q-1} \beta_q \times trt_{ij}^q$$

where d_{ijk} corresponds to the event indicator of patient j ($j=1, \dots, n_i$) in trial i ($i=1, \dots, N$) during period k ($k=1, \dots, K$). It takes the value of 0 or 1. It is modeled by a Poisson process for each patient of each trial during each time period. The constant $\log(\xi_{ijk})$ is the time at risk of patient j in trial i during period k and is included as an offset in the model. Parameters π_k ($\pi \in R^K$) and γ_i ($\gamma \in R^N$) correspond respectively to the study specific adjustment for study i and to the baseline hazard rate during the k th time period.

Variables trt_{ij}^q are the treatment contrast comparing treatment q to a fixed reference treatment and can take the values 0, 1 or -1. For example, in a trial i comparing the q -th treatment versus the p -th treatment, contrast variable can take the following values for a patient j in the experimental arm:

$$trt_{ij}^q = 1$$

$$trt_{ij}^p = -1$$

$$trt_{ij}^l = 0 \quad (l \neq p \text{ and } l \neq q)$$

Finally, parameter β_q corresponds to the log hazard ratio for the q-th treatment versus the reference treatment. Under the consistency hypothesis, it allows the reconstruction of log hazard ratio for every possible pairwise treatment comparison:

$$\log HR_{q \text{ vs } p} = \beta_q - \beta_p$$

To decrease computation time of Poisson modelling for IPD NMA, it is possible to collapse individual data across treatments, periods and covariates patterns, with d_{ijk} corresponding then to the number of events in the i-th study during the k-th period in subjects belonging the j-th pattern of covariates (for example : male of the experimental arm). The same Poisson regression model can be fitted to this collapsed dataset giving exactly the same parameter estimates as the Poisson regression model fitted to the non-collapsed dataset. This process is however limited to the case where all covariates are categorical.

Penalized Poisson model and between-trial heterogeneity

Between-trial heterogeneity of treatment effect for a particular comparison is usually taken into account by including a random effect into the statistical model for each treatment comparison. When multiple treatment comparisons (edges) are included in the network, the inference will quickly become very complex with multiple integrations. We propose a penalized fixed effects model as an alternative to this inference issue.

For a NMA, random effects can be included in the Poisson regression previously described in the following manner:

$$\begin{aligned} \log(\mu_{ijk}) &= \log(\xi_{ijk}) + \pi_k + \gamma_i + \sum_{q=1}^{Q-1} \beta_{qi} \times \text{trt}_{ij}^q \\ \gamma_i &= \bar{\gamma} + u_i \text{ with } u_i \sim \mathcal{N}(0, \sigma^2) \\ \beta_{qi} &= \bar{\beta}_q + v_{qi} \text{ with } v_{qi} \sim \mathcal{N}(0, \tau_q^2) \end{aligned} \quad (1)$$

Where $\bar{\gamma} \in R$ and $\bar{\beta} \in R^{Q-1}$ correspond to the average baseline hazard and relative treatment effects. Hidden variables $(u_i)_{i=1, \dots, N}$ and $(v_{qi})_{i=1, \dots, N}$ correspond to study specific random effects. Parameters σ^2 and $(\tau_q^2)_{q=1, \dots, Q-1}$ correspond to the between-trial variance for baseline hazard and relative treatment effects, respectively.

The vector of fixed effect parameter $\theta = (\pi, \bar{\gamma}, \bar{\beta})$ and σ^2 and $(\tau_q^2)_{q=1, \dots, Q-1}$ could be estimated by solving the following maximum likelihood problem:

$$\underset{\theta, \sigma^2, \tau_q^2}{\operatorname{argmin}} \left\{ -\log \iint P(d, u, v) \, du \, dv \right\}$$

where $P(d, u, v)$ represents the complete data likelihood written as follows:

$$\begin{aligned}
& -\log P(d, u, v) \propto -\log P(d|\theta, u, v) - \log P(u, v|\theta) \\
& \propto -\log P(d|\theta, u, v) + \frac{N}{2} \log(\sigma^2) + \frac{1}{2\sigma^2} \|u\|_2^2 + \sum_q \left(\frac{N}{2} \log(\tau_q^2) + \frac{1}{2\tau_q^2} \|v_q\|_2^2 \right)
\end{aligned}$$

with $P(d|\theta, u, v)$ the Poisson likelihood of the observation given θ, u and v

$$\log P(d|\theta, u, v) = \sum_{i,j,k} \left(d_{ijk} \times \log(\mu_{ijk}) + \mu_{ijk} - \log(d_{ijk}!) \right)$$

and $\|\cdot\|_2^2$ is the Euclidian norm.

This mixed Poisson model (equation 1) can be used to derive a penalized Poisson regression problem in which hidden variables u and v are treated as fixed effects.

$$\log(\mu_{ijk}) = \log(\xi_{ijk}) + \pi_k + (\bar{y} + u_i) + \sum_{q=1}^{Q-1} (\bar{\beta}_q + v_{qi}) \times \text{trt}_{ij}^q \quad (2)$$

$$\underset{\theta, u, v_q}{\text{argmin}} \left\{ -\log P(d|\theta, u, v) + \frac{\lambda_0}{2} \|u\|_2^2 + \sum_q \frac{\lambda_q}{2} \|v_q\|_2^2 \right\} \quad (3)$$

where λ_0 and $(\lambda_q)_{q=1, \dots, Q-1}$ are the penalization parameters. These penalization parameters are linked to between-trial variances of random effects:

$$\lambda_0 = \frac{1}{\sigma^2} \text{ and } \lambda_q = \frac{1}{\tau_q^2} \quad (q = 1, \dots, Q - 1) \quad (4)$$

Within this framework, estimation of θ, u and v can be obtained easily by estimating a fixed penalized Poisson regression problem which is computationally less intensive than solving equation 1.

Penalization parameters can be calibrated¹⁴ by solving iteratively problem (2) and updating values λ_0 and $(\lambda_q)_{q=1, \dots, Q-1}$:

$$\begin{aligned}
\left(\begin{array}{c} \theta_{n+1} \\ u_{n+1} \\ (v_{q,n+1})_{q=1, \dots, Q-1} \end{array} \right) &= \underset{\theta, u, v_q}{\text{argmin}} \left\{ -\log P(d|\theta, u, v) + \frac{\lambda_0^n}{2} \|u\|_2^2 + \sum_q \frac{\lambda_q^n}{2} \|v_q\|_2^2 \right\} \\
\lambda_0^n &= \frac{df_{u_n}}{u_n^t u_n} \\
\lambda_q^n &= \frac{df_{v_{q,n}}}{(v_{q,n})^t v_{q,n}}
\end{aligned}$$

with df_{u_n} and $df_{v_{q,n}}$ the respective degrees of freedom of u_n and $v_{q,n}$

$$\begin{aligned}
df_{u_n} &= \text{Trace}(H_{u_n, u_n}) \\
df_{v_{q,n}} &= \text{Trace}(H_{v_{q,n}, v_{q,n}})
\end{aligned}$$

The matrix H corresponds to the hat matrix and is defined as:

$$H = \left[\frac{\partial^2 \log P(d|\Theta)}{\partial \Theta^t \partial \Theta} - \text{diag}(\lambda) \right]^{-1} \left[\frac{\partial^2 \log P(d|\Theta)}{\partial \Theta^t \partial \Theta} \right]$$

with $\Theta = (\theta, u, v)$ and $\lambda = (0, \dots, 0, \lambda_0, \lambda_{q=1, \dots, q-1})$ the vector of regularization parameter for each component of Θ . The Q+K first component of vector λ are 0 as parameters in θ ($\theta \in R^{Q+K}$) are not penalized. In the case of Poisson regression, the hessian matrix is:

$$\frac{\partial^2 \log P(d|\Theta)}{\partial \Theta^t \partial \Theta} = X^t \text{diag}(\mu) X$$

With d and μ the vectors of events indicators and Poisson rates, respectively. The matrix X corresponds to the design matrix of the linear predictor:

$$\begin{aligned} d &\sim \mathcal{P}(\mu) \\ \log(\mu) &= \log(\xi) + X\Theta \end{aligned}$$

Parameters selection with adaptive lasso penalty

In IPD NMA, treatment effect needs to be estimated without selection and are then always included in the model. But some parameters accounting for inconsistency, covariates or covariate-treatment interactions effects and non-proportionality of treatment effects do not have to be systematically included in the model. The goal of the modelling process is then to perform variable selection on these particular effects.

The use of the penalized Poisson regression framework presented before allows to include L_1 norm penalty to perform variable selection¹⁵. Therefore, several terms can be added in the Poisson regression model respectively to take into account:

i) Inconsistency

$$\sum_{q < p} \omega_{qp} \times |trt_{ij}^q \times trt_{ij}^p|$$

With ω_{qp} the parameter that quantify inconsistency in the loop defined by the q-th and the p-th treatments.

ii) Covariates effect

$$\sum_{c=1}^C \delta_c \times z_{ijc}$$

With z_{ijc} the values of the c-th covariates for the j-th patient of the i-th trial and δ_c the parameter that quantify the effect of the c-th covariates on baseline hazard.

iii) Covariate-by-treatment interactions

$$\sum_{q=1}^{Q-1} \sum_{c=1}^C \alpha_{cq} \times z_{ijc} \times trt_{ij}^q$$

With α_{cq} the parameter that quantify the effect of the interaction between the c-th covariates and the q-th treatment.

iv) Non-proportionality of treatments effects

The non-proportionality of treatment effects is modelling as a time-by-treatment interaction with time divided into K intervals considering the first time interval (k=1) as the reference:

$$\sum_{q=1}^{Q-1} \sum_{k=2}^K \zeta_{kq} \times trt_{ij}^q \times 1_{t \in \mathcal{P}_k}$$

With ζ_{kq} the parameter that quantify the effect of the interaction between the k-th follow-up period and the q-th treatment and $1_{t \in \mathcal{P}_k}$ the indicator variable of the k-th time period.

When all these terms are added to the Poisson regression model (2), we obtain the following model:

$$\begin{aligned} \log(\mu_{ijk}) = & \log(\xi_{ijk}) + \pi_k + (\bar{\gamma} + u_i) + \sum_{q=1}^{Q-1} (\bar{\beta}_q + v_{qi}) \times trt_{ij}^q + \sum_{q < p} \omega_{qp} \times |trt_{ij}^q \times trt_{ij}^p| \\ & + \sum_{c=1}^C \delta_c \times z_{ijc} + \sum_{q=1}^{Q-1} \sum_{c=1}^C \alpha_{cq} \times z_{ijc} \times trt_{ij}^q + \sum_{q=1}^{Q-1} \sum_{k=2}^K \zeta_{kq} \times trt_{ij}^q \times 1_{t \in \mathcal{P}_k} \end{aligned}$$

As parameters ω , δ , α and ζ have to be selected, we penalize the likelihood (3) using an adaptive Lasso penalty¹⁶ (weighted L₁ norm) on these parameters:

$$\operatorname{argmin}_{\theta, u, v_q} \left\{ \begin{aligned} & -\log P(d|\theta, u, v) + \frac{\lambda_0}{2} \|u\|_2^2 + \sum_q \frac{\lambda_q}{2} \|v_q\|_2^2 \\ & + \lambda_{L_1} (\| \rho_{\hat{\omega}} \circ \omega \|_1 + \| \rho_{\hat{\delta}} \circ \delta \|_1 + \| \rho_{\hat{\alpha}} \circ \alpha \|_1 + \| \rho_{\hat{\zeta}} \circ \zeta \|_1) \end{aligned} \right\} \quad (5)$$

with \circ the Hadamard product and λ_{L_1} the coefficient that tune the degree of sparsity in the final estimates of ω , δ , α and ζ . The vector of fixed effects is now $\theta = (\pi, \bar{\gamma}, \bar{\beta}, \omega, \delta, \alpha, \zeta)$. Penalty weights ρ_{ω} , ρ_{δ} , ρ_{α} and ρ_{ζ} of the adaptive lasso penalty can be computed using unpenalized estimates of ω , δ , α and ζ obtain with λ_{L_1} equal or close to 0:

$$\rho_{\omega} = \frac{1}{\hat{\omega}_{UnPen}}, \rho_{\delta} = \frac{1}{\hat{\delta}_{UnPen}}, \rho_{\alpha} = \frac{1}{\hat{\alpha}_{UnPen}} \text{ and } \rho_{\zeta} = \frac{1}{\hat{\zeta}_{UnPen}}$$

For a fixed value of λ_{L_1} , penalization parameters λ_0 and $(\lambda_q)_{q=1,\dots,Q-1}$ are calibrated by solving iteratively problem 5 with updated values λ_0 and $(\lambda_q)_{q=1,\dots,Q-1}$:

$$\begin{pmatrix} \theta_{n+1} \\ u_{n+1} \\ (v_{q,n+1})_{q=1,\dots,Q-1} \end{pmatrix} = \underset{\theta, u, v_q}{\operatorname{argmin}} \left\{ \begin{aligned} & -\log P(d|\theta, u, v) + \frac{\lambda_0^n}{2} \|u\|_2^2 + \sum_q \frac{\lambda_q^n}{2} \|v_q\|_2^2 \\ & + \lambda_{L_1} (\|\rho_{\hat{\omega}} \circ \omega\|_1 + \|\rho_{\hat{\delta}} \circ \delta\|_1 + \|\rho_{\hat{\alpha}} \circ \alpha\|_1 + \|\rho_{\hat{\zeta}} \circ \zeta\|_1) \end{aligned} \right\}$$

$$\lambda_0^n = \frac{df_{u_n}}{u_n^t u_n}$$

$$\lambda_q^n = \frac{df_{v_{q,n}}}{(v_{q,n})^t v_{q,n}}$$

At each iteration, the solution of this penalized optimization problem could be solved using the R package `penalized` as it allows to penalize each parameter with different types of penalty (L1, L2 or both).

Shrinkage coefficient λ_{L_1} is selected using a two-step BIC approach¹⁷. The first step corresponds to the evaluation of the solution of problem (5) for a grid of user-defined λ_{L_1} values. In a second step, the models selected with each λ_{L_1} values of the grid are re-estimated without L₁ penalty. The optimal λ_{L_1} value is the one that minimizes the BIC calculated with a degree of freedom set to:

$$df = \operatorname{Trace}(H_{S_{\hat{\theta}}, S_{\hat{\theta}}})$$

with $S_{\hat{\theta}}$ the support of the estimated vector of parameters $\hat{\Theta} = (\hat{\theta}, \hat{u}, \hat{v})$.

The standard errors of the regression coefficients were estimated by using a nonparametric bootstrap approach.

Simulation framework

We performed a simulation study to evaluate estimation accuracy and selection model performance of the penalized Poisson approach in the framework of IPD NMA for time-to-event data. Simulation were based on a non-trivial network of 5 treatments (A, B, C, D and E) with several loops. The geometry of the network is represented in figure 2 (5 nodes and 9 edges). This structure was chosen to avoid identifiability problem due to structure of the network in order to avoid confusion between the performance of the proposed method and structural identifiability problems. Treatment A was considered as the reference treatment with direct comparison with treatments B, C, D, and E. IPD time-to-event data were simulated using the R package `survsim`¹⁸. Event and censoring times were both simulated using an exponential distribution with scale parameter set to -7. For each pairwise comparison, 10 trials

were considered with a sample size drawn from a uniform distribution (U(50,500)). The coefficients associated to each treatment contrast variable were set to: $\bar{\beta}_{B \text{ vs } A} = \log(0.77)$, $\bar{\beta}_{C \text{ vs } A} = \log(0.65)$, $\bar{\beta}_{D \text{ vs } A} = \log(0.96)$, $\bar{\beta}_{E \text{ vs } A} = \log(0.87)$. These treatment effects correspond to moderate effect size. Treatment effects for other comparisons were derived from basic parameters and consistency hypothesis. Standard deviation of between-trial heterogeneity for baseline hazard was set to $\sigma = 0.2$. Standard deviation of between-trial heterogeneity $(\tau_q)_{q=B,\dots,E}$ were considered equal for each comparison with the reference treatment and different values were considered (0.1, 0.2, 0.3, 0.4 and 0.5). We considered two binary covariates (C=2) simulated from a Bernoulli distribution with a probability of 0.5. The follow-up time was divided in K=6 periods. We simulated 5 scenarios with increasing complexity according to different model specifications (true model). These specifications represent different situations in terms of inconsistency, covariates, covariate-treatment interaction and non-proportionality parameters (Table 1). Scenario 1 represent a simple NMA with no inconsistency, covariate, covariate-treatment interaction and non-proportionality of treatment effects ($\omega = 0$, $\delta = 0$, $\alpha = 0$ and $\zeta = 0$). Scenario 2 represents a NMA with inconsistency in two treatments loops but without covariate, covariate-treatment interaction and non-proportionality of treatment effects. Inconsistency is simulated in treatments loops ABC and ADE. Scenario 3 represents a NMA with a covariate and two covariate-treatment interactions effects without inconsistency and non-proportionality of treatment effects. Scenario 4 represents a NMA with inconsistency, covariate and covariate-treatment interaction effects without non-proportionality. Scenario 5 represent a NMA with both inconsistency, covariate, covariate-by-treatment interactions and non-proportionality of treatment effects. Inconsistency, covariates and covariate-treatment interactions were parametrized in the same way as in scenario 4. Treatment E was considered to have a non-proportional treatment effect compared to reference treatment A. As the survsim package does not allow to implement directly non proportional treatment effects, we used a different baseline hazard for subject receiving treatment E compared to the other subjects. This trick allows to simulate the time-dependent of treatment effect for treatment E. In arms involving treatment E, a Weibull hazard with shape parameter set to 0.75 was used to simulate event times. The other arms were supposed to follow an exponential hazard as previously described.

For each scenario and each between-trial heterogeneity levels, we simulated 100 data sets. We applied the proposed penalized adaptive lasso procedure (HetAdLASSO) on each simulated data set. Between-trial heterogeneity was evaluated on baseline hazard and each treatments contrast. In order to assess the impact of between-trial heterogeneity on model selection performances, we also applied an adaptive lasso procedure that does not take into account for between-trial variability (FxADLASSO for Fixed Adaptive Lasso). This latter consists in excluding from HetAdLASSO the terms associated to u and v .

The criteria for the evaluation of the selection model performances were accuracy (proportion of the model that is correctly identified), false positive rate (FPR, proportion of non-influent parameters that are selected) and false negative rate (FNR, proportion of influent parameters that are not selected). We also evaluated the proportion of correctly selected model according to each specification of the true model (inconsistency, covariates, covariate-treatment interactions and non-proportionality). Lastly, in simulations where the true model for a given scenario was selected, we estimated the absolute bias of (i) each treatment contrast for the 2 approaches and (ii) the variance of the between-trial heterogeneity of treatment effects returned by HetAdLASSO. Both procedures (FxADLASSO and HetAdLASSO) were implemented using the R package `penalized`¹⁹ and our R code is available in supplementary materials.

RESULTS

Simulation study

Figure 3 represents selection accuracy, FNR and FPR of both adaptive LASSO methods for the different simulated scenarios with increasing between-trial heterogeneity of treatment effects. Overall, selection accuracy of HetAdLASSO is close to 100% and does not seem to be influenced by the level of between-trial variance. When between-trial heterogeneity is not taken into account (FxADLASSO), selection accuracy decreased for increasing between-trial variance. The decreasing selection accuracy of FxADLASSO was mainly driven by an increased false positive rate. On the contrary, an increasing between-trial variance tends to increase the FNR of HetAdLASSO mainly driven by the non-detection of inconsistency terms.

Figure 4 represents the proportion of times both methods recovered the true model according to the parameter types (covariates, covariate-by-treatments interactions, inconsistency and non-proportionality) in the different simulated scenarios. Covariate parameters were correctly selected for both methods and do not seem to be affected by the level of between-trial variance. Concerning covariate-treatment interactions parameters, FxADLASSO performances decreased slightly with between-trial heterogeneity of treatment effects. Major differences between FxADLASSO and HetAdLASSO methods were observed for the selection of inconsistency and non-proportionality parameters. For scenario with moderate and high between-trial heterogeneity values, selection performance decreases mainly driven by the issue of inconsistency detection for both methods. FxADLASSO selected falsely positive inconsistency terms whereas HetAdLASSO was more conservative and fails to detect significant inconsistency term (false negative). FxADLASSO approach fails also to select the correct non-proportionality model with decreasing performance for increasing between-trial heterogeneity. This is not the case of HetAdLASSO approach. Overall, FxADLASSO performed also well with low between-trial heterogeneity except for inconsistency characteristic, but selection accuracy decreases with increasing between-trial heterogeneity mainly driven by an increased false positive rate. Taking the between-trial heterogeneity into account with the HetAdLASSO significantly increased selection performance.

Figure 5 represents the box plot of absolute bias for log-hazard ratio $(\bar{\beta}_q)_{q=1,\dots,Q}$ parameters obtained with both methods in simulations where the true model was selected whatever the scenario (56.7% for HetAdLASSO and 8.4% for FxAdLASSO). FxAdLASSO tends to return biased estimates when between-trial heterogeneity increased. FxAdLASSO never returned the true model when between-trial standard deviation was set to 0.5. Using HetAdLASSO allows to reduce this bias problem and also to reduce its variability.

Finally, it is also possible to compare the true values of between-trial standard deviation $(\tau_q)_{q=1,\dots,Q}$ to the estimated values from the penalization parameters $(\lambda_q)_{q=1,\dots,Q}$ obtained using the iterative procedure $(\tau_q = \sqrt{\frac{1}{\lambda_q}})$. Figure 6 represents the absolute bias obtained in 1422 data set for which HetAdLASSO selected the true model. In these simulations, the HetAdLASSO method allows a good estimation of between-trial standard deviations of treatment effect although it was not directly design for.

Application to IPD network meta-analysis of chemotherapy and radiotherapy in nasopharyngeal carcinoma

We applied HetAdLASSO and FxAdLASSO methods to overall survival data of the IDP NMA in nasopharyngeal carcinoma. Due to the network's structure and the limited number of trials in some comparisons then: i) no between-trials heterogeneity was estimated for IC_RT_AC treatment contrast (only one trial evaluated IC_RT_AC) and ii) only one inconsistency parameter was estimated, in the loop defined by treatments CRT and CRT_AC. Adding inconsistency parameter in the other loops would lead to identifiability issues especially for HetAdLASSO. Five covariates were included in the analysis: age (treated as a continuous covariate), sex (male (reference), female), Tumor size stage (T1 (reference), T2, T3 and T4), node invasion stage (N0 (reference), N1, N2 and N3) and radiotherapy technique (2D (reference), 2.5D, 3D and IMRT). Categorical covariates were converted to indicator variables. Follow-up time was divided in K=4 periods. Covariate-by-treatment interactions were investigated for each treatment contrast and covariates. This makes a total number of 84 parameters subject to the selection process and penalized by the lasso penalty.

Models respectively selected with HetAdLASSO and FxAdLASSO methods are summarized in Table 2. None of the methods selected covariate-by-treatment interactions and non-proportionality parameters. Only FxAdLASSO selected the parameter of inconsistency for the loop defined by treatments RT, CRT and CRT_AC. Concerning covariates, HetAdLASSO selected age, sex, tumor size stage T4 and node invasion stage N3 as influent covariates. FxAdLASSO

selected 3 additional covariates: IMRT radiotherapy technique, tumor size stage T3 and node invasion stage N2. These results are coherent with the previous simulation study, in which FxAdLASSO tended to select more complex model. Table 3 summarized parameters estimates obtained with both methods. Treatments effect estimates of HetAdLASSO are coherent with the ones obtained with the two-stage analysis previously published⁶ except for the treatment effect comparing IC_RT_AC modality to RT. This difference could be explained by a lack of data, as data from one of the two trials evaluating IC_RT_AC in the original publication was not available for this analysis (investigators did not allow the use of their data for methodological research). The best treatment (lowest hazard ratios) seems to be CRT_AC and is the same in all analyses. Estimates of between-trials heterogeneity of treatment effect, obtained using equation 4, seems negligible in all treatment (tau≤0.05) contrast except for CRT with tau=0.34.

Discussion

Network of meta-analysis of individual patient time-to-event data represents the state-of-the-art approach for evidence synthesis of time-to-event outcomes. However, conducting such an analysis necessitates to perform a model selection procedure to identify influent covariates, covariates-treatment integration, inconsistency and non-proportionality parameters. The literature on the subject is relatively sparse. One of the major difficulties being taking into account the between-trials heterogeneity which could influence the selection process. This work presented a penalized Poisson model in which between trials differences are treated as fixed effects which allows to take into account between trials heterogeneity.

The proposed method faces two main limitations. First, our method corresponds to a penalized regression approach and then does not return directly standard errors of parameters estimation and confidence intervals. However, such quantities can be easily obtained by using bootstrap. Re-estimation of the selected model using a generalized linear mixed model may be a possibility, but the calculation of confidence intervals was prohibitively long (> 1 hour) in our NMA data of nasopharyngeal carcinoma data.

Secondly, our method does not provide a direct estimation of between trial variances. Our approach corresponds to an empirical Bayesian method that rely on the empirical variance of the posterior mode of between trials differences (u and v). Based on estimated values of penalization parameters λ_0 and $(\lambda_q)_{q=1,\dots,Q-1}$, equation 4 could be used to return an approximation of between trial variances. For data sets with a large number of trials with large sample sizes, these values may be a good approximation as posterior distribution of between trials differences u and v are asymptotically normal²⁰. This was the case in our simulation study. However, with fewer trials or more limited sample sizes posterior distributions of between trials differences may be skewed; the posterior mode and posterior mean of between trials differences may then differ significantly. In such a case, the empirical variance

of posterior mode of u and v may provide a biased estimation of between trial variances. This phenomenon does not appear in the EM-algorithm as the calculation of between trial variances are based on conditional mean of u and v .

In order to explore the presence of ecological bias, it has been proposed to decompose covariate-by-treatment interactions in a within and a between trial interactions^{9,21}. We do not consider such a decomposition in our work, but this could be directly implemented in the proposed method. Moreover, specific parameters for between trial interactions interaction terms could also be penalized using a lasso penalty and then be included in the selection procedure.

Finally, treatments effects were not penalized as would shrink coefficient toward zero and then biased treatments effect estimates. However, in a selection perspective, it may be interesting to detect treatments that have the same effect. This would be possible by penalizing treatments effects using a fusion penalty that penalize difference between treatments effects^{22,23} and then promote sparsity in the difference between parameters.

Conclusion

To conclude, in this work we developed a penalized Poisson method to select network meta-analysis model based on individual patient time-to-event data. Our approach takes into account between trials heterogeneity without using the framework of mixed effect models that are computationally more intensive especially for large datasets encountered in meta-analysis of individual patient time-to-event data.

Acknowledgement

EO thanks the Nuovo Soldati Fellowship Fund for its support.

The authors would like to thank the MAC-NPC Collaborative Group (cf. Ribassin-Majed et al.⁶ for the list of its members) who allowed to use the data for methodological research.

Data Availability Statement

The nasopharyngeal carcinoma data that support the findings of this study are not publicly available. Restrictions apply to the availability of these data. Data requests should be made to Gustave Roussy.

References

1. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. *Stat Med.* 2002;21:371-387.
2. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. *J Clin Epidemiol.* 2002;55:86-94.
3. Debray T P, Schuit E, Efthimiou O et al. An overview of methods for network meta-analysis using individual participant data: when do benefits arise? *Statistical methods in medical research*, 2018;27(5):1351-64.
4. Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? *PLoS One.* 2013;8(4):e60650.
5. Freeman SC, Carpenter JR. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models. *Research synthesis methods*, 2017;8(4):451-464.
6. Ribassin-Majed L, Marguet S, Lee AWM, Tong Ng W, Ma J, Chan ATC, Yu Huang P, Zhu G, Chua TT, Chen Y, Qiang Mai H, Kwong DLW, Lee Cheah S, Moon J, Tung Y, Kwan-Hwa C, Fountzilas G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *J Clin Oncol*, 2017;35(5):498-505.
7. Crowther MJ, Riley RD, Staessen JA, Wang J, Gueyffier F, Lambert PC. Individual patient data meta-analysis of survival data using Poisson regression models. *BMC Medical Research Methodology*, 2012;12(1):34.
8. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. *J Am Stat Assoc.* 2006;101(474):447-459.
9. Freeman SC, Fisher D, Tierney JF, Carpenter JR. A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis. *Research synthesis methods*, 2018;9(3):393-407.
10. Groll, A., & Tutz, G. Variable selection for generalized linear mixed models by L 1-penalized estimation. *Statistics and Computing*, 2014;24(2):137-154.
11. Schelldorfer J, Meier L, Bühlmann P. Glmmlasso: an algorithm for high-dimensional generalized linear mixed models using ℓ_1 -penalization. *Journal of Computational and Graphical Statistics*, 2014;23(2):460-477.
12. Fort G, Ollier E, Samson A. Stochastic proximal-gradient algorithms for penalized mixed models. *Statistics and Computing*, 2019;29(2):231-253.

13. Ollier E, Viallon V. Regression modelling on stratified data with the lasso. *Biometrika*, 2017;104(1):83-96.
14. Perperoglou A. Cox models with dynamic ridge penalties on time-varying effects of the covariates. *Statistics in medicine*, 2014;33(1):170-180.
15. Tibshirani R. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society: Series B (Methodological)*, 1996;58(1):267-288.
16. Zou, H. The adaptive lasso and its oracle properties. *Journal of the American statistical association*, 2006;101(476):1418-1429.
17. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. *The Annals of statistics*, 2004;32(2):407-499.
18. Moriña D, Navarro A. The R package survsim for the simulation of simple and complex survival data. *Journal of Statistical Software*, 2014;59(2):1-20.
19. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. *Biometrical journal*, 2010;52(1):70-84.
20. Baghishani H, Mohammadzadeh M. Asymptotic normality of posterior distributions for generalized linear mixed models. *Journal of Multivariate Analysis*, 2012;111:66-77.
21. Hua H, Burke DL, Crowther MJ, Ensor J, Tudur Smith C, Riley RD. One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information. *Statistics in medicine*, 2017;36(5):772-789.
22. Ollier E, Samson A, Delavenne X, Viallon V. A SAEM algorithm for fused lasso penalized non-linear mixed effect models: application to group comparison in pharmacokinetics. *Computational Statistics and Data Analysis*, 2016;95:207-221.
23. Viallon V, Lambert-Lacroix S, Höfling H, Picard F. On the robustness of the Generalized Fused Lasso to prior specifications. *Statistics and Computing*, 2016;26(1):285-301.

Figure 1 Treatments network of the data set for chemotherapy timing in nasopharyngeal carcinoma. The number of trials (t) and number patients (pts) is shown for each comparison.




Figure 2 Structure of the network used for the simulation study.




Figure 3 Selection accuracy, False Positive Rate (FPR) and False Negative Rate (FNR) obtained in the various designs for both adaptive LASSO methods : i) adaptive LASSO method that takes into account between study heterogeneity (HetAdLASSO) and ii) adaptive LASSO method that do not take into account between study heterogeneity (FxADLASSO). Red solid lines represent the results of HetAdLASSO. Yellow solid lines represent the results of FxADLASSO.




Figure 4 Proportion of times over the 100 simulated data sets that FxAdLASSO and HetAdLASSO selected the true model. Results are stratified on parameters type: covariates, covariates-treatments interactions, inconsistency and non-proportionality. Red solid lines represent the results of HetAdLASSO. Yellow solid lines represent the results of FxAdLASSO.




Figure 5 Absolute bias for log-hazard ratio $(\bar{\beta}_q)_{q=1,\dots,Q}$ parameters estimates obtained with FxAdLASSO and HetAdLASSO methods in data sets where the true model was selected whatever the scenario. Red boxplots represent the results of HetAdLASSO. Yellow boxplots represent the results of FxAdLASSO




Figure 6 Absolute bias for between-trial standard deviation ($(\tau_q)_{q=1,\dots,Q}$) estimations using the optimal values of penalty parameters ($(\lambda_q)_{q=1,\dots,Q}$) in data set where the true model was selected




Table 1: Simulation parameters of the five scenarios

Scenarios	Inconsistency	Covariate	Covariate-treatment interaction	Non-proportionality of risks
S1	$\omega = 0$	$\delta = 0$	$\alpha = 0$	$\zeta = 0$
S2	Treatments loops ABC and ADE. $\omega_{BC} = \log(0.5)$, $\omega_{DE} = \log(2)$ and 0 elsewhere	$\delta = 0$	$\alpha = 0$	$\zeta = 0$
S3	$\omega = 0$	$\delta = (0, \log(1.25))$	$\alpha_{2B} = \log(1.25)$, $\alpha_{2D} = \log(1.25)$ and 0 elsewhere.	$\zeta = 0$
S4	Treatments loops ABC and ADE. $\omega_{BC} = \log(0.5)$, $\omega_{DE} = \log(2)$ and 0 elsewhere.	$\delta = (0, \log(1.25))$	$\alpha_{2B} = \log(1.25)$, $\alpha_{2D} = \log(1.25)$ and 0 elsewhere.	$\zeta = 0$
S5	Treatments loops ABC and ADE. $\omega_{BC} = \log(0.5)$, $\omega_{DE} = \log(2)$ and 0 elsewhere.	$\delta = (0, \log(1.25))$	$\alpha_{2B} = \log(1.25)$, $\alpha_{2D} = \log(1.25)$ and 0 elsewhere.	$\zeta_E \neq 0$

Table 2: Model selected with fixed adaptive Lasso (FxADLASSO) and random adaptive Lasso (HetAdLASSO) methods for the individual patient data network meta-analysis of chemotherapy and radiotherapy in nasopharyngeal carcinoma.

	FxADLASSO	HetAdLASSO
Covariates	$\delta_{Age}, \delta_{Sex}, \delta_{T3}, \delta_{T4}, \delta_{N2}, \delta_{N3}, \delta_{IMRT}$	$\delta_{Age}, \delta_{Sex}, \delta_{T4}, \delta_{N3}$
Covariates-by-treatment interactions	None	None
Inconsistency	$\omega_{CRT\ CRT_AC}$	None
Non proportionality	None	None

Table 3: Unpenalized re-estimations of the model selected using fixed adaptive lasso (FxADLASSO) and random adaptive lasso (HetAdLASSO) methods. Confidence intervals were computed using bootstrap. The column ‘Two step NMA’ reports the results from the two-step network meta-analysis (NMA) previously published by Ribassin-Majed (ref). In this publication, the hazard ratios of relative treatment effects were estimated by using the Peto estimator.

	Two step NMA	FxADLASSO	HetAdLASSO
Treatment effects			
$HR_{IC_RT \text{ Vs } RT}$	0.92 [0.75 ; 1.12]	0.99 [0.84 ; 1.16]	0.94 [0.77 ; 1.16]
$HR_{IC_CRT \text{ Vs } RT}$	0.81 [0.63 ; 1.04]	0.89 [0.72 ; 1.11]	0.84 [0.63 ; 1.11]
$HR_{CRT \text{ Vs } RT}$	0.77 [0.64 ; 0.92]	0.75 [0.64 ; 0.87]	0.76 [0.55 ; 1.05]
$HR_{CRT_AC \text{ Vs } RT}$	0.65 [0.56 ; 0.75]	0.67 [0.59 ; 0.77]	0.63 [0.54 ; 0.73]
$HR_{RT_AC \text{ Vs } RT}$	0.96 [0.71 ; 1.29]	0.89 [0.70 ; 1.11]	0.93 [0.69 ; 1.25]
$HR_{IC_RT_AC \text{ Vs } RT}$	0.87 [0.58 ; 1.30]	1.46 [0.83 ; 2.34]	1.28 [0.68 ; 2.42]
Between trial standard deviation			
τ_{IC_RT}			0.05
τ_{IC_CRT}			0.05
τ_{CRT}	-	-	0.34
τ_{CRT_AC}			0.04
τ_{RT_AC}			0.05
Inconsistency (Hazard ratio)			
$\omega_{CRT \text{ CRT_AC}}$	-	0.44 [0.28 ; 0.68]	-
Covariates (Hazard ratio)			
Age (year)	-	1.03 [1.03 ; 1.04]	1.03 [1.02 ; 1.03]
Sex (Ref : Male)	-	0.79 [0.71 ; 0.88]	0.79 [0.71 ; 0.88]
T3 (Ref : T1)	-	1.35 [1.21 ; 1.51]	-
T4 (Ref : T1)	-	2.04 [1.83 ; 2.28]	1.47 [1.33 ; 1.62]
N2 (Ref : N0)	-	1.63 [1.46 ; 1.81]	-
N3 (Ref : N0)	-	2.52 [2.23 ; 2.85]	1.62 [1.46 ; 1.80]
IMRT (Ref : no IMRT)	-	0.55 [0.38 ; 0.78]	-